A Study of DB-1303 vs Investigator’s Choice Chemotherapy in Metastatic Breast Cancer

A Study of DB-1303 vs Investigator’s Choice Chemotherapy in Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
Interventions: Drug: DB-1303; Drug: Capecitabine; Drug: Paclitaxel; Drug: Nab-paclitaxel
Sponsors: DualityBio Inc.
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 18, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments